Amarin Corporation PLCNASDAQ
Advanced Chart
  • May 29, 2013, 9:58 AM
    AstraZeneca's (AZN -1.5%) $443M deal to acquire Omthera puts the U.K. company at "distinct commercial advantage" over Amarin (AMRN +0.3%), says Decision Resources' Paramjit Narang. Omthera's Epanova drug "offers higher and more constant bioavailability, and arguably better efficacy" in lowering triglyceride than Amarin's Vascepa, and it "lacks the gastrointestinal side effects of the market incumbent Lovaza," which is sold by GSK (GSK -2%). Narang reckons Epanova's annual sales could peak at $1B.
    | May 29, 2013, 9:58 AM | 9 Comments
  • Nov. 16, 2012, 2:30 PM

    Shares of Amarin (AMRN -4.4%) spike lower after the FDA's latest Orange Book update shows no change in the status of its fish-oil pill Vascepa. M&A speculators had been optimistic on a decision from regulators over the exclusivity of the pill would be coming this month, because last week a draft response letter made the rounds around the FDA which made no mention of 'no decision' this month, as it has previously before.

    | Nov. 16, 2012, 2:30 PM | 5 Comments
  • Nov. 15, 2012, 8:28 AM
    Amarin (AMRN) +9% following a report that Teva (TEVA +0.7%) is leading the race to acquire the Irish biotech, which has a market cap of $1.6B, with AstraZeneca (AZN +0.4%) also in the hunt. Teva recently said it wasn't intending to make any major acquisitions, while it's also due to unveil a long-term overhaul in December.
    | Nov. 15, 2012, 8:28 AM | 3 Comments
  • Mar. 15, 2012, 12:26 PM

    Sparking gains in Irish biotech firm Amarin (AMRN +8.6%) is a Leerink Swann note speculating that "patent progress could solidify Amarin as a prime takeout candidate given the blockbuster potential for [heart-drug candidate] AMR-101." The firm had earlier said AMRN was moving toward winning its quest for U.S. patent protection for AMR-101.

    | Mar. 15, 2012, 12:26 PM | 1 Comment
  • Jan. 17, 2012, 11:38 AM

    Amarin (AMRN +6.6%) jumps after Jefferies (Buy) says it has learned the company would prefer either to sell itself, or commercialize its AMR101 drug on its own, than to enter into a royalty-bearing partnership for AMR101. Management is said to be concerned about the challenges involved in negotiating a partnership.

    | Jan. 17, 2012, 11:38 AM